A cutting-edge study published in npj Breast Cancer today reports validation of the HER2DX genomic test as a robust prognostic tool in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and a taxane (THP).
🔬 What was done: Researchers combined real-world data from 215 patients across Spanish and Polish cohorts. They assessed baseline tumor tissue using the HER2DX assay to derive genomic scores linked to outcomes in patients receiving standard first-line HER2-targeted therapy (THP).
📊 Key findings:
• A high ERBB2 mRNA score was associated with significantly longer progression-free and overall survival, as well as higher objective response rates — independent of traditional clinical variables.
• The team developed a HER2DX metastatic prognostic score that outperformed ERBB2 mRNA levels alone in predicting outcomes, suggesting genomic profiling can further refine risk stratification in advanced disease.
📈 Implications: This study supports the clinical utility of HER2DX in identifying patients with HER2-positive advanced breast cancer who might derive the greatest benefit from existing first-line therapies — and highlights the growing role of genomic tools in precision oncology.
Rodrigo Arrangoiz, MD
Surgical Oncologist, Mount Sinai Medical Center (MSMC)
My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida.
I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016.
Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida.
Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.
View all posts by Rodrigo Arrangoiz MS, MD, FACS, FSSO
Rodrigo Arrangoiz MS, MD, FACS, FSSO 